Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 442

1.

Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29].

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2017 Dec 7. pii: S1521-6616(17)30854-9. doi: 10.1016/j.clim.2017.11.012. [Epub ahead of print] No abstract available.

PMID:
29195081
2.

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.

Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A.

RMD Open. 2017 Nov 1;3(2):e000515. doi: 10.1136/rmdopen-2017-000515. eCollection 2017.

3.

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P.

RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017.

4.

Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.

Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE.

Rheumatology (Oxford). 2017 Oct 23. doi: 10.1093/rheumatology/kex403. [Epub ahead of print]

PMID:
29069471
5.

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.

Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF.

Ann Rheum Dis. 2017 Oct 13. pii: annrheumdis-2017-212196. doi: 10.1136/annrheumdis-2017-212196. [Epub ahead of print]

6.

Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do.

Seror R, Mariette X.

Rheumatology (Oxford). 2017 Oct 1;56(10):1641-1642. doi: 10.1093/rheumatology/kex320. No abstract available.

PMID:
28957571
7.

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J.

Rheumatology (Oxford). 2017 Oct 1;56(10):1746-1754. doi: 10.1093/rheumatology/kex238.

PMID:
28957557
8.

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial.

Sigaux J, Bailly F, Hajage D, Mariette X, Morel J, Gandjbakhch F, Foltz V, Gossec L, Tubach F, Fautrel B.

RMD Open. 2017 Sep 12;3(2):e000474. doi: 10.1136/rmdopen-2017-000474. eCollection 2017.

9.

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.

Mariette X, Chen C, Biswas P, Kwok K, Boy MG.

Arthritis Care Res (Hoboken). 2017 Sep 21. doi: 10.1002/acr.23421. [Epub ahead of print]

PMID:
28941219
10.

The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.

Calabrese L, Mariette X.

Ann Rheum Dis. 2017 Sep 19. pii: annrheumdis-2017-212061. doi: 10.1136/annrheumdis-2017-212061. [Epub ahead of print]

PMID:
28928270
11.

Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome.

Wang-Renault SF, Boudaoud S, Nocturne G, Roche E, Sigrist N, Daviaud C, Bugge Tinggaard A, Renault V, Deleuze JF, Mariette X, Tost J.

Ann Rheum Dis. 2018 Jan;77(1):133-140. doi: 10.1136/annrheumdis-2017-211417. Epub 2017 Sep 15.

12.

Role of the IL-12/IL-35 balance in patients with Sjögren syndrome.

Fogel O, Rivière E, Seror R, Nocturne G, Boudaoud S, Ly B, Gottenberg JE, Le Guern V, Dubost JJ, Nititham J, Taylor KE, Chanson P, Dieudé P, Criswell LA, Jagla B, Thai A, Mingueneau M, Mariette X, Miceli-Richard C.

J Allergy Clin Immunol. 2017 Sep 12. pii: S0091-6749(17)31434-3. doi: 10.1016/j.jaci.2017.07.041. [Epub ahead of print]

PMID:
28916184
13.

Certolizumab, an anti-TNF safe during pregancy? The CRIB Study results: an interview with Professor Xavier Mariette.

Mariette X.

Immunotherapy. 2017 Sep;9(10):793-795. doi: 10.2217/imt-2017-0099.

PMID:
28877634
14.

Association of the Presence of Anti-Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome: Data From the French ESPOIR Cohort.

Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, Blanco P, Mahler M, Contin-Bordes C, Schaeverbeke T; Fédération Hospitalo-Universitaire ACRONIM.

Arthritis Rheumatol. 2017 Dec;69(12):2292-2302. doi: 10.1002/art.40237.

PMID:
28853240
15.

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.

Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.

16.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2017 Aug 12. pii: S1521-6616(17)30543-0. doi: 10.1016/j.clim.2017.08.009. [Epub ahead of print]

PMID:
28811201
17.

Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Alarcón-Riquelme M, Mariette X, Lessard CJ, Harley JB, Ng WF, Rasmussen A, Sivils KL, Scofield RH.

Arthritis Rheumatol. 2017 Nov;69(11):2187-2192. doi: 10.1002/art.40207. Epub 2017 Oct 12.

PMID:
28692793
18.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.

Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

19.

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.

Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10.

PMID:
28646772
20.

Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons.

Li H, Reksten TR, Ice JA, Kelly JA, Adrianto I, Rasmussen A, Wang S, He B, Grundahl KM, Glenn SB, Miceli-Richard C, Bowman S, Lester S, Eriksson P, Eloranta ML, Brun JG, Gøransson LG, Harboe E, Guthridge JM, Kaufman KM, Kvarnström M, Cunninghame Graham DS, Patel K, Adler AJ, Farris AD, Brennan MT, Chodosh J, Gopalakrishnan R, Weisman MH, Venuturupalli S, Wallace DJ, Hefner KS, Houston GD, Huang AJW, Hughes PJ, Lewis DM, Radfar L, Vista ES, Edgar CE, Rohrer MD, Stone DU, Vyse TJ, Harley JB, Gaffney PM, James JA, Turner S, Alevizos I, Anaya JM, Rhodus NL, Segal BM, Montgomery CG, Scofield RH, Kovats S, Mariette X, Rönnblom L, Witte T, Rischmueller M, Wahren-Herlenius M, Omdal R, Jonsson R, Ng WF; for UK Primary Sjögren's Syndrome Registry, Nordmark G, Lessard CJ, Sivils KL.

PLoS Genet. 2017 Jun 22;13(6):e1006820. doi: 10.1371/journal.pgen.1006820. eCollection 2017 Jun.

Supplemental Content

Loading ...
Support Center